



CORPORATE PROFILE

Knight Therapeutics Inc. (TSX: GUD) is a pan-American (ex-USA) specialty pharmaceutical company focused on acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets with over 150 products and over 20 partners. Knight's Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. Knight is headquartered in Montreal, Quebec, Canada and has over 800 employees.

OUR FOOTPRINT



Over \$450M in Revenue
Over \$452M in Adjusted Revenue¹



11 Countries plus distributors
in Central America and the Caribbean



+800 Employees



+150 Products
>25 Pipeline & early launch products



+20 Partners



3 Manufacturing Plants
1 R&D Center
1 Regional Distribution Center

MARKET FACTS

(As at March 19, 2026)
TSX: GUD
Share Price: \$6.10
Shares Outstanding: 98 M
Market Capitalization: \$598 M

MANAGEMENT TEAM

Samira Sakhia
President and CEO

Amal Khouri
Chief Business Officer

Arvind Utchanah
Chief Financial Officer

Susan Emblem
Global VP Human Resources

Monica Percario
Global VP Regulatory and Quality

Leopoldo Bosano
Global VP Manufacturing and Operations

Henrique Dias
Global VP Marketing

Melanie Groleau
Global VP Medical and Clinical

BOARD OF DIRECTORS

Jonathan Ross Goodman
(Executive Chairman)

James Gale (Lead Director)

Samira Sakhia

Robert Lande

Janice Murray

Michael Tremblay

Nicolás Sujoy

INVESTOR CONTACT

Samira Sakhia
Tel: 514.484.4483

Arvind Utchanah
Tel: 598.2626.2344

E-mail: IR@knighttx.com
Website: www.knighttx.com

FINANCIAL RESULTS

In '000s of CAD except per share amounts

	Q4 2025	Q4 2024	2025	2024
Revenues	133,106	96,864	450,088	371,304
Cash inflow from operations	34,872	1,469	68,957	36,280
<i>Non-GAAP measures:</i>				
Adjusted Revenue ^{1,2}	133,203	94,066	452,351	365,412
Adjusted EBITDA ^{1,3}	24,449	14,996	73,056	57,783
Per share ^{1,3}	0.25	0.15	0.74	0.58
	12-31-2025	12-31-2024		
Net cash ⁴ , marketable securities and financial assets	125,818	232,878		
Per share	1.27	2.30		
Net asset value	767,272	795,105		
Per share	7.74	7.86		


¹ Adjusted Revenue, Adjusted EBITDA and Adjusted EBITDA per share are non-GAAP measures and do not have any standardized meaning under GAAP. As a result, the information presented may not be comparable to similar measures presented by other companies. Refer to Section 9 — Financial Results under Non-GAAP measures in the 2025 Management's Discussion and Analysis for additional details.

² Adjusted Revenue excludes the impact of hyperinflationary accounting (IAS29).


³ Adjusted EBITDA is operating income (loss) adjusted to exclude amortization and impairment of non-current assets, depreciation, impact of IAS 29 (accounting under hyperinflation), acquisition cost and non-recurring expenses but to include costs related to leases. Adjusted EBITDA per share is a non-GAAP ratio and calculated as adjusted EBITDA over number of common shares outstanding at the end of the respective period.

⁴ Net of bank loans

ADJUSTED REVENUE¹ BY PRODUCT PORTFOLIO




ADJUSTED REVENUE¹ BY GEOGRAPHY



ADJUSTED REVENUE¹ BY GEOGRAPHY



FINANCIAL HIGHLIGHTS



¹ Adjusted Revenues, Adjusted EBITDA and CAGR on Adjusted Revenues are non-GAAP measures and do not have any standardized meaning under GAAP. As a result, the information presented may not be comparable to similar measures presented by other companies. Refer to Section 9 — Financial Results under Non-GAAP measures in the 2025 Management's Discussion and Analysis for additional details.

² Growth as CAGR on Adjusted Revenue represents the compound annual growth rate, calculated as $(\text{Adjusted Revenue for 2025} \div \text{Adjusted Revenue for 2020})^{(1/\text{number of years})} - 1$.

CORPORATE RESPONSIBILITY

Knight continues to work diligently to expand patient access to its medications across its markets, while developing branded generic products for Latin America to ensure that Knight provides cost effective treatments.

INVESTMENT HIGHLIGHTS

- Strong regional infrastructure with a unique footprint in Canada and across 11 countries in Latin America
- Experienced and dynamic management team
- Proven ability to develop a rich pipeline of new products and to secure mutually beneficial transactions
- Proven track record of profitable growth
- Financial strength to execute our strategy

ANALYST COVERAGE

Bloom Burton & Co.
David Martin
dmartin@bloomburton.com

Canaccord Genuity
Tania Armstrong-Whitworth
tarmstrongwhitworth@cgf.com

Raymond James
Michael Freeman
michael.freeman@raymondjames.ca

Stifel GMP
Justin Keywood
jkeywood@stifel.com

Research Capital
Andre Uddin
auddin@researchcapital.com

Paradigm Capital Inc
Scott McAuley
smcauley@paradigmcap.com

RBC Capital Markets
Douglas Miehm
douglas.miehm@research.rbccm.com

¹ Adjusted Revenue is a non-GAAP measure and does not have any standardized meaning under GAAP. As a result, the information presented may not be comparable to similar measures presented by other companies. Refer to Section 9 — Financial Results under Non-GAAP measures in the Management's Discussion and Analysis for additional details.